Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) National Security (14)
- (-) Neutron Science (6)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (2)
- Biology and Environment (11)
- Clean Energy (20)
- Computational Engineering (1)
- Computer Science (2)
- Fusion and Fission (1)
- Isotopes (6)
- Materials (15)
- Materials for Computing (2)
- Quantum information Science (1)
- Supercomputing (23)
News Topics
- (-) Artificial Intelligence (7)
- (-) Biomedical (6)
- (-) Cybersecurity (9)
- (-) Grid (1)
- (-) Isotopes (2)
- (-) Machine Learning (4)
- 3-D Printing/Advanced Manufacturing (6)
- Advanced Reactors (3)
- Big Data (1)
- Bioenergy (5)
- Biology (5)
- Biotechnology (1)
- Chemical Sciences (2)
- Climate Change (1)
- Composites (1)
- Computer Science (14)
- Coronavirus (5)
- Decarbonization (2)
- Energy Storage (3)
- Environment (4)
- Exascale Computing (1)
- Frontier (2)
- Fusion (3)
- High-Performance Computing (2)
- Materials (7)
- Materials Science (14)
- Microscopy (1)
- Nanotechnology (6)
- National Security (11)
- Neutron Science (40)
- Nuclear Energy (9)
- Partnerships (4)
- Physics (8)
- Quantum Science (4)
- Security (6)
- Space Exploration (3)
- Summit (4)
- Sustainable Energy (3)
- Transformational Challenge Reactor (1)
- Transportation (3)
Media Contacts
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.